Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 3
2006 4
2007 4
2008 1
2010 6
2011 5
2012 3
2013 4
2014 5
2015 15
2016 8
2017 7
2018 11
2019 9
2020 10
2021 10
2022 6
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 27069169

98 results

Results by year

Filters applied: . Clear all
Page 1
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Al-Batran SE, Lange T, Dietrich G, Stoehlmacher J, Tannapfel A, Reinacher-Schick A, Quidde J, Trarbach T, Hinke A, Schmoll HJ, Arnold D. Hegewisch-Becker S, et al. Lancet Oncol. 2015 Oct;16(13):1355-69. doi: 10.1016/S1470-2045(15)00042-X. Epub 2015 Sep 8. Lancet Oncol. 2015. PMID: 26361971 Clinical Trial.
Safety, tolerability, and efficacy of oxaliplatin-based adjuvant chemotherapy after curative resection of hepatic or extrahepatic metastases of Stage IV colorectal cancer.
Nakayama I, Suenaga M, Wakatsuki T, Ichimura T, Ozaka M, Takahari D, Shinozaki E, Chin K, Ueno M, Mizunuma N, Yamaguchi T. Nakayama I, et al. Cancer Chemother Pharmacol. 2015 Jul;76(1):133-9. doi: 10.1007/s00280-015-2780-1. Epub 2015 May 21. Cancer Chemother Pharmacol. 2015. PMID: 25994854
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, Lee JI, Shin DB, Ji J, Chen JS, Lim Y, Ha S, Bang YJ; CLASSIC trial investigators. Noh SH, et al. Lancet Oncol. 2014 Nov;15(12):1389-96. doi: 10.1016/S1470-2045(14)70473-5. Epub 2014 Oct 15. Lancet Oncol. 2014. PMID: 25439693 Clinical Trial.
98 results